BiotechTV - News

CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with Merck/MSD, and R&D products targeting HSV and BKV.

She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his take on the potential most favored nation policy, companies with negative enterprise values, and China competition.

He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA today), and geographic atrophy.

He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus learnings from year two of a physician survey, and his current take on CAR-T for autoimmune and CD123 for AML.

Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a third-generation TKI, and highiglights Bcl-2 and EED.

CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an EHA presentation from an early access program that is a follow-up from data we saw in ASH in December.

Matthew Lungren describes his belief how AI will "save time before it saves lives," and discusses how the clinical workforce is getting more used to adopting it. Plus how AI might affect cancer care and drug development R&D.

He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety. Plus, recent #AACR25 data on BTK, BRAF and Aurora A, and his toughts on STAT6, IRAK4, and other autoimmune targets.

He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the company's Nectin-4 ADC, and Monalizumab.

CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account pixels that may be unseen by the human eye.

BiotechTV attended the event, and recorded comments from the Nucleate team, who describe the scale and role of Nucleate in this area. We hear about the Activator program, and meet entrepreneurs who have benefitted from it. Plus, how Nucleate has partnered with the government's Advanced Research and Invention Agency (ARIA) in the UK.

CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine how certain patients and ethnic groups will respond to therapies in the real world. and what is next for Artera.

He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.

Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in context of this cancer type and stage that historically has had a very poor prognosis.

Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps.

He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this program in other cancers.

He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer immunotherapies. He covers the data, and describes how Strand is seeing the abscopal effect in some patients for this intra-tumoral administered product.

CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.

Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.

He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically, and how Deerfield is adding new people to both participate in it and invest in it.

He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC announcement that JNJ made in March, and guides for when Protagonist will announce an obesity program.

She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.

He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.